guest ::
| Home > Publications database > The shared frameshift mutation landscape of microsatellite-unstable cancers suggests immunoediting during tumor evolution. > print |
| Home > Publications database > The shared frameshift mutation landscape of microsatellite-unstable cancers suggests immunoediting during tumor evolution. > print |
| 001 | 163651 | ||
| 005 | 20240229123154.0 | ||
| 024 | 7 | _ | |a 10.1038/s41467-020-18514-5 |2 doi |
| 024 | 7 | _ | |a pmid:32958755 |2 pmid |
| 024 | 7 | _ | |a altmetric:90841104 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2020-01929 |
| 041 | _ | _ | |a eng |
| 082 | _ | _ | |a 500 |
| 100 | 1 | _ | |a Ballhausen, Alexej |0 0000-0002-5470-4973 |b 0 |e First author |
| 245 | _ | _ | |a The shared frameshift mutation landscape of microsatellite-unstable cancers suggests immunoediting during tumor evolution. |
| 260 | _ | _ | |a [London] |c 2020 |b Nature Publishing Group UK |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1634822034_5773 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a #EA:F210#LA:F210# |
| 520 | _ | _ | |a The immune system can recognize and attack cancer cells, especially those with a high load of mutation-induced neoantigens. Such neoantigens are abundant in DNA mismatch repair (MMR)-deficient, microsatellite-unstable (MSI) cancers. MMR deficiency leads to insertion/deletion (indel) mutations at coding microsatellites (cMS) and to neoantigen-inducing translational frameshifts. Here, we develop a tool to quantify frameshift mutations in MSI colorectal and endometrial cancer. Our results show that frameshift mutation frequency is negatively correlated to the predicted immunogenicity of the resulting peptides, suggesting counterselection of cell clones with highly immunogenic frameshift peptides. This correlation is absent in tumors with Beta-2-microglobulin mutations, and HLA-A*02:01 status is related to cMS mutation patterns. Importantly, certain outlier mutations are common in MSI cancers despite being related to frameshift peptides with functionally confirmed immunogenicity, suggesting a possible driver role during MSI tumor evolution. Neoantigens resulting from shared mutations represent promising vaccine candidates for prevention of MSI cancers. |
| 536 | _ | _ | |a 316 - Infections and cancer (POF3-316) |0 G:(DE-HGF)POF3-316 |c POF3-316 |f POF III |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, |
| 700 | 1 | _ | |a Przybilla, Moritz Jakob |0 P:(DE-He78)2c6d4f81ba6891f170d25801c181ace1 |b 1 |e First author |
| 700 | 1 | _ | |a Jendrusch, Michael |0 P:(DE-HGF)0 |b 2 |e First author |
| 700 | 1 | _ | |a Haupt, Saskia |0 0000-0001-7537-9439 |b 3 |
| 700 | 1 | _ | |a Pfaffendorf, Elisabeth |0 P:(DE-HGF)0 |b 4 |
| 700 | 1 | _ | |a Seidler, Florian |0 P:(DE-He78)42ccf6cd47fe67a45f6c7ba82ef71cb4 |b 5 |
| 700 | 1 | _ | |a Witt, Johannes |0 P:(DE-HGF)0 |b 6 |
| 700 | 1 | _ | |a Hernandez Sanchez, Alejandro |0 P:(DE-He78)ae2b0ea140ce90582429c65ca3f07ddf |b 7 |
| 700 | 1 | _ | |a Urban, Katharina |0 P:(DE-He78)9cafc6ecff7e1f32c9d4644c841740cb |b 8 |
| 700 | 1 | _ | |a Draxlbauer, Markus |0 P:(DE-He78)8f193082367ba9aa5c54634703b1864f |b 9 |
| 700 | 1 | _ | |a Krausert, Sonja |0 P:(DE-He78)6e11760c6fdd0c35cd056cf36243ecd5 |b 10 |
| 700 | 1 | _ | |a Ahadova, Aysel |0 P:(DE-He78)07eef6d38a91f4642c810745c5bf5000 |b 11 |
| 700 | 1 | _ | |a Kalteis, Martin Simon |0 P:(DE-He78)f56b635d86a04c198398be3a2ba9e561 |b 12 |
| 700 | 1 | _ | |a Pfuderer, Pauline |0 P:(DE-He78)d5d04ce2423a9de1689951cf098cd32c |b 13 |
| 700 | 1 | _ | |a Heid, Daniel |0 P:(DE-HGF)0 |b 14 |
| 700 | 1 | _ | |a Stichel, Damian |0 P:(DE-He78)d20d08adc992abdb6ccffa1686f1ba17 |b 15 |
| 700 | 1 | _ | |a Gebert, Johannes |0 P:(DE-He78)c826cd3421c6d05725b35568f80b4c67 |b 16 |
| 700 | 1 | _ | |a Bonsack, Maria |0 P:(DE-He78)ec22a465429f245d6ef43a2329223262 |b 17 |
| 700 | 1 | _ | |a Schott, Sarah |b 18 |
| 700 | 1 | _ | |a Bläker, Hendrik |b 19 |
| 700 | 1 | _ | |a Seppälä, Toni |0 0000-0002-4940-3498 |b 20 |
| 700 | 1 | _ | |a Mecklin, Jukka-Pekka |b 21 |
| 700 | 1 | _ | |a Ten Broeke, Sanne |b 22 |
| 700 | 1 | _ | |a Nielsen, Maartje |b 23 |
| 700 | 1 | _ | |a Heuveline, Vincent |0 0000-0002-2217-7558 |b 24 |
| 700 | 1 | _ | |a Krzykalla, Julia |0 P:(DE-He78)5a7a75d1b29b770f98f1bb2062fc3df9 |b 25 |
| 700 | 1 | _ | |a Benner, Axel |0 P:(DE-He78)e15dfa1260625c69d6690a197392a994 |b 26 |
| 700 | 1 | _ | |a Riemer, Angelika |0 P:(DE-He78)3743a1b712edca2ffa829b7096d7037e |b 27 |
| 700 | 1 | _ | |a von Knebel Doeberitz, Magnus |0 P:(DE-He78)11747cd1dc061b9333c0e3a3ff31bf2f |b 28 |
| 700 | 1 | _ | |a Kloor, Matthias |0 P:(DE-He78)028ee60cca729028708496826f077b58 |b 29 |e Last author |
| 773 | _ | _ | |a 10.1038/s41467-020-18514-5 |g Vol. 11, no. 1, p. 4740 |0 PERI:(DE-600)2553671-0 |n 1 |p 4740 |t Nature Communications |v 11 |y 2020 |x 2041-1723 |
| 909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:163651 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 0 |6 0000-0002-5470-4973 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 1 |6 P:(DE-He78)2c6d4f81ba6891f170d25801c181ace1 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 2 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 4 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 5 |6 P:(DE-He78)42ccf6cd47fe67a45f6c7ba82ef71cb4 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 6 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 7 |6 P:(DE-He78)ae2b0ea140ce90582429c65ca3f07ddf |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 8 |6 P:(DE-He78)9cafc6ecff7e1f32c9d4644c841740cb |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 9 |6 P:(DE-He78)8f193082367ba9aa5c54634703b1864f |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 10 |6 P:(DE-He78)6e11760c6fdd0c35cd056cf36243ecd5 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 11 |6 P:(DE-He78)07eef6d38a91f4642c810745c5bf5000 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 12 |6 P:(DE-He78)f56b635d86a04c198398be3a2ba9e561 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 13 |6 P:(DE-He78)d5d04ce2423a9de1689951cf098cd32c |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 14 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 15 |6 P:(DE-He78)d20d08adc992abdb6ccffa1686f1ba17 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 16 |6 P:(DE-He78)c826cd3421c6d05725b35568f80b4c67 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 17 |6 P:(DE-He78)ec22a465429f245d6ef43a2329223262 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 25 |6 P:(DE-He78)5a7a75d1b29b770f98f1bb2062fc3df9 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 26 |6 P:(DE-He78)e15dfa1260625c69d6690a197392a994 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 27 |6 P:(DE-He78)3743a1b712edca2ffa829b7096d7037e |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 28 |6 P:(DE-He78)11747cd1dc061b9333c0e3a3ff31bf2f |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 29 |6 P:(DE-He78)028ee60cca729028708496826f077b58 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF3-310 |0 G:(DE-HGF)POF3-316 |3 G:(DE-HGF)POF3 |2 G:(DE-HGF)POF3-300 |4 G:(DE-HGF)POF |v Infections and cancer |x 0 |
| 914 | 1 | _ | |y 2020 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b NAT COMMUN : 2018 |d 2020-01-16 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2020-01-16 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2020-01-16 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0310 |2 StatID |b NCBI Molecular Biology Database |d 2020-01-16 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0320 |2 StatID |b PubMed Central |d 2020-01-16 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0501 |2 StatID |b DOAJ Seal |d 2020-01-16 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0500 |2 StatID |b DOAJ |d 2020-01-16 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b DOAJ : Peer review |d 2020-01-16 |
| 915 | _ | _ | |a Creative Commons Attribution CC BY (No Version) |0 LIC:(DE-HGF)CCBYNV |2 V:(DE-HGF) |b DOAJ |d 2020-01-16 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2020-01-16 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1060 |2 StatID |b Current Contents - Agriculture, Biology and Environmental Sciences |d 2020-01-16 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1040 |2 StatID |b Zoological Record |d 2020-01-16 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0110 |2 StatID |b Science Citation Index |d 2020-01-16 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2020-01-16 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0111 |2 StatID |b Science Citation Index Expanded |d 2020-01-16 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2020-01-16 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2020-01-16 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2020-01-16 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1150 |2 StatID |b Current Contents - Physical, Chemical and Earth Sciences |d 2020-01-16 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2020-01-16 |
| 915 | _ | _ | |a IF >= 10 |0 StatID:(DE-HGF)9910 |2 StatID |b NAT COMMUN : 2018 |d 2020-01-16 |
| 915 | _ | _ | |a Article Processing Charges |0 StatID:(DE-HGF)0561 |2 StatID |f 2020-01-16 |
| 915 | _ | _ | |a Fees |0 StatID:(DE-HGF)0700 |2 StatID |d 2020-01-16 |
| 920 | 1 | _ | |0 I:(DE-He78)F210-20160331 |k F210 |l Angewandte Tumorbiologie |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)B300-20160331 |k B300 |l KKE Neuropathologie |x 1 |
| 920 | 1 | _ | |0 I:(DE-He78)F130-20160331 |k F130 |l F130 Immuntherapie und -prävention |x 2 |
| 920 | 1 | _ | |0 I:(DE-He78)C060-20160331 |k C060 |l C060 Biostatistik |x 3 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)F210-20160331 |
| 980 | _ | _ | |a I:(DE-He78)B300-20160331 |
| 980 | _ | _ | |a I:(DE-He78)F130-20160331 |
| 980 | _ | _ | |a I:(DE-He78)C060-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|